FDA: Immune Tx Monotherapy in Bladder Ca May Worsen Survival

(MedPage Today) -- Pembrolizumab, atezolizumab trials stop enrolling patients with low PD-L1
Source: MedPage Today Public Health - Category: American Health Source Type: news